Nick Rogers

Nick Rogers serves as a procurement professional within the CDC Office of Acquisition Services, supporting the agency’s mission to safeguard public health through strategic acquisition of critical scientific and diagnostic capabilities. He manages a diverse portfolio of contracts focused on laboratory instrumentation, in-vitro diagnostics, and biomedical research services, ensuring timely access to technologies that enable disease surveillance, outbreak response, and public health data operations. His work directly facilitates the deployment of high-complexity testing systems and analytical platforms essential to national health security. Rogers maintains established relationships with leading contractors including General Dynamics Information Technology, Cepheid, GlaxoSmithKline, New York City Health & Hospitals Corp, and MRIGLOBAL, partnering with firms that deliver advanced diagnostic equipment, clinical testing services, and life sciences R&D support. His contracting approach emphasizes technical rigor, regulatory compliance, and performance-based outcomes, often engaging vendors with proven expertise in FDA-cleared devices and CLIA-compliant laboratory systems. These partnerships are sustained through long-term, mission-aligned procurement strategies that prioritize reliability and scalability. His procurement patterns reflect a strong preference for open competition, with 93.2% of awards issued without set-asides, indicating a focus on technical merit and market capability over socioeconomic preferences. While small business participation remains modest—primarily through Total Small Business Set-Asides (4.5%) and Women-Owned Small Business awards (2.3%)—his approach aligns with CDC’s need for specialized, high-capacity vendors capable of meeting complex public health demands. Rogers’ technical focus centers on NAICS 334516 (analytical laboratory instrument manufacturing), 541380 (testing laboratories), and 325413 (in-vitro diagnostic substance manufacturing), reflecting deep expertise in procuring molecular diagnostics, automated analyzers, and clinical testing infrastructure. His work ensures CDC’s laboratories remain equipped with cutting-edge tools for pathogen detection, genomic sequencing, and real-time public health monitoring.